Literature DB >> 30346092

Characterization of the hepatosplenic and portal venous findings in patients with Proteus syndrome.

Varun Takyar1, Divya Khattar2, Alexander Ling3, Rachna Patel2, Julie C Sapp2, Sun A Kim4, Sungyoung Auh5, Leslie G Biesecker2, Kim M Keppler-Noreuil2, Theo Heller1.   

Abstract

Proteus syndrome (PS) is a rare disorder caused by a mosaic AKT1 variant that comprises patchy overgrowth of tissues derived from all three germinal layers affecting multiple viscera. We sought to delineate the extent of hepatoportal manifestations in patients with PS. We identified patients with PS who had abdominal imaging from 1989 to 2015 in a natural history study. Imaging was characterized for evidence of focal findings in the liver, spleen, and portal vasculature and for organomegaly. Relevant clinical and laboratory data were compared among those with or without organomegaly. Abdominal imaging was available on 38 patients including 20 who had serial studies. Nine patients had focal hepatic lesions including vascular malformations (VMs). Focal splenic abnormalities were noted in seven patients. Patients without cutaneous VMs did not have visceral VMs. Nine patients had splenomegaly, 12 had portal vein dilation, and 4 had hepatomegaly. There was a weak correlation of portal vein dilation to spleen height ratio (r2 = 0.18, p < .05). On laboratory evaluation, hepatic function was normal but there was thrombocytopenia in those with splenomegaly; platelet counts were 179 ± 87K/μL compared to those with normal spleen size at 253 ± 57K/μL (p < .05). Overall, focal hepatosplenic abnormalities occurred in 11 of 38 (29%) patients with PS. Splenomegaly and portal venous dilation were both found in 8 of 38 (21%) patients; however, other than relative thrombocytopenia, there was no evidence of portal hypertension. Although the AKT1-E17K somatic variant is a suspected oncogene, there were no malignant lesions identified in this study. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  AKT1 mutation; Proteus syndrome; overgrowth syndromes; vascular malformations

Mesh:

Substances:

Year:  2018        PMID: 30346092      PMCID: PMC8020299          DOI: 10.1002/ajmg.a.40636

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  34 in total

1.  Screening Hepatoblastoma in Beckwith-Wiedemann Syndrome: A Complex Issue.

Authors:  Alessandro Mussa; Giovanni Battista Ferrero
Journal:  J Pediatr Hematol Oncol       Date:  2015-11       Impact factor: 1.289

Review 2.  The challenges of Proteus syndrome: diagnosis and management.

Authors:  Leslie Biesecker
Journal:  Eur J Hum Genet       Date:  2006-08-02       Impact factor: 4.246

3.  Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease.

Authors:  Meral Gunay-Aygun; Esperanza Font-Montgomery; Linda Lukose; Maya Tuchman Gerstein; Katie Piwnica-Worms; Peter Choyke; Kailash T Daryanani; Baris Turkbey; Roxanne Fischer; Isa Bernardini; Murat Sincan; Xiongce Zhao; Netanya G Sandler; Annelys Roque; Daniel C Douek; Jennifer Graf; Marjan Huizing; Joy C Bryant; Parvathi Mohan; William A Gahl; Theo Heller
Journal:  Gastroenterology       Date:  2012-10-03       Impact factor: 22.682

4.  Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia.

Authors:  R H Aster
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

5.  Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells.

Authors:  L Rössig; A S Jadidi; C Urbich; C Badorff; A M Zeiher; S Dimmeler
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

6.  PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.

Authors:  Kim M Keppler-Noreuil; Jonathan J Rios; Victoria E R Parker; Robert K Semple; Marjorie J Lindhurst; Julie C Sapp; Ahmad Alomari; Marybeth Ezaki; William Dobyns; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2014-12-31       Impact factor: 2.802

7.  Sudden death caused by pulmonary thromboembolism in Proteus syndrome.

Authors:  A M Slavotinek; S J Vacha; K F Peters; L G Biesecker
Journal:  Clin Genet       Date:  2000-11       Impact factor: 4.438

8.  Normal liver, spleen, and kidney dimensions in neonates, infants, and children: evaluation with sonography.

Authors:  O L Konuş; A Ozdemir; A Akkaya; G Erbaş; H Celik; S Işik
Journal:  AJR Am J Roentgenol       Date:  1998-12       Impact factor: 3.959

9.  Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients.

Authors:  K Devaney; Z D Goodman; K G Ishak
Journal:  Am J Surg Pathol       Date:  1994-11       Impact factor: 6.394

10.  Lack of mutation-histopathology correlation in a patient with Proteus syndrome.

Authors:  Meggie E Doucet; Hadley M Bloomhardt; Krzysztof Moroz; Marjorie J Lindhurst; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2016-04-26       Impact factor: 2.802

View more
  3 in total

1.  Ubiquitous expression of Akt1 p.(E17K) results in vascular defects and embryonic lethality in mice.

Authors:  Marjorie J Lindhurst; Wenling Li; Nathaniel Laughner; Jasmine J Shwetar; Hannah C Kondolf; Xuefei Ma; Yoh-Suke Mukouyama; Leslie G Biesecker
Journal:  Hum Mol Genet       Date:  2020-12-18       Impact factor: 6.150

2.  A mouse model of Proteus syndrome.

Authors:  Marjorie J Lindhurst; Lauren R Brinster; Hannah C Kondolf; Jasmine J Shwetar; Miranda R Yourick; Henoke Shiferaw; Kim M Keppler-Noreuil; Gene Elliot; Cecilia Rivas; Lisa Garrett; Julio Gomez-Rodriguez; Neil J Sebire; Stephen M Hewitt; Pamela L Schwartzberg; Leslie G Biesecker
Journal:  Hum Mol Genet       Date:  2019-09-01       Impact factor: 6.150

3.  Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.

Authors:  Kim M Keppler-Noreuil; Jay Lozier; Neal Oden; Anjali Taneja; Jasmine Burton-Akright; Julie C Sapp; Leslie G Biesecker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-09-06       Impact factor: 3.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.